07 Apr BioCity Glasgow based Amphista Therapeutics raises $7.5m Series A round
Amphista’s potent bifunctional small molecules augment targeted protein degradation Investors include Advent Life Sciences, the Scottish Investment Bank, the European Investment Fund and US-based BioMotiv Glasgow, Scotland, 7 April 2020 – Amphista Therapeutics, a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body’s natural processes...